Avadel Pharmaceuticals (NASDAQ:AVDL) reported strong Q2 2025 financial results, with LUMRYZ™ generating $68.1 million in net revenue, marking a 64% increase year-over-year. The company achieved its first quarterly net income of $9.7 million ($0.10 per share) since LUMRYZ's 2023 launch.
Key highlights include 3,100 patients on LUMRYZ as of June 30, 2025 (63% YoY increase), and raised 2025 revenue guidance to $265-275 million. The company received FDA Orphan Drug Designation for LUMRYZ in Idiopathic Hypersomnia (IH) and expects to complete enrollment in the Phase 3 REVITALYZ™ study by end of 2025.
The company's cash position strengthened to $81.5 million, with positive cash flow and a $15.0 million increase from Q1 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.